COMP <GO>
UHS vs LLY // PIOTROSKI F-SCORE QUALITY
Universal Health Services Inc. (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: UHS 4
— LLY 9
■ METRIC PARITY
LAST: $176.05 (-0.32%) • MKT CAP: $10.41B
piotroski-score
9/9
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
piotroski-score
9/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UHS VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | UHS | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 83.64% | -42.64 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.10% | 32.36% | -18.26 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 5.0x | 36.4x | -31.42 | UHS | /valuation <GO> |
| Free Cash Flow Yield | 8.16% | 2.30% | +5.86 | UHS | /fcf-yield <GO> |
| Operating Margin | 11.50% | 40.21% | -28.71 | LLY | /operating-margins <GO> |
| Net Profit Margin | 8.60% | 31.90% | -23.30 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 9.70% | 45.51% | -35.81 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.49% | 0.49% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.11 | 9.29 | -6.18 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.00% | 6.77% | +0.23 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.7 | 77.9 | -32.22 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.04 | 0.51 | +0.53 | UHS | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.5x | 26.3x | -19.75 | UHS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.41B | $1.33T | -$1.32T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | UHS REV | LLY REV | UHS GROSS % | LLY GROSS % | UHS FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $17.36B | $65.18B | 44.0% | 83.0% | $849.2M | $16.81B |
| FY 2024 | $15.83B | $45.04B | 44.0% | 81.3% | $1.12B | $8.82B |
| FY 2023 | $14.28B | $34.12B | 44.0% | 79.3% | $625.1M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UHS // BETA 1.04
LLY // BETA 0.51